期刊文献+

靶向HIF-1α基因的CRISPR/Cas9基因敲除质粒的构建与鉴定 被引量:3

Construction and indentification of CRISPR/Cas9 plasmid targeting HIF-1α gene
下载PDF
导出
摘要 目的:构建靶向低氧诱导因子(HIF)-1α基因的CRISPR/Cas9基因敲除质粒,并体外鉴定其敲除效果。方法:设计靶向HIF-1α基因的gRNA序列,将其插入到CRISPR/Cas9质粒骨架载体p CAG-T7中,转化后挑取克隆,进行测序验证。将构建好的重组质粒体外转染人肝癌细胞Hep G2和SK-Hep-1,利用嘌呤霉素进行筛选并扩大培养获得HIF-1α基因敲除混合克隆细胞,应用Western blot技术检测未转染细胞和混合克隆细胞中HIF-1α蛋白的表达情况。结果:经测序验证,成功构建了靶向HIF-1α的重组质粒p CAG-T7-HIF-1α-gRNA,经Western blot验证,转染该重组质粒后人肝癌细胞株Hep G2和SK-Hep-1经Co Cl2诱导HIF-1α蛋白表达明显减弱。结论:成功构建了靶向HIF-1α基因的CRISPR/Cas9基因敲除质粒载体。 Aim: To construct CRISPR/Cas9 knock-out plasmid targeting HIF-1α gene,and identify its knock-out effect in vitro. Methods: The gRNA sequences targeting HIF-1α gene were designed,then were inserted into CRISPR/Cas9 plasmid skeleton vector p CAG-T7,which was transformed into competent DH5α. The single clone was picked up and validated via sequencing. Then the constructed recombinant vector p CAG-T7-HIF-1α-gRNA was transfected into Hep G2 and SKHep-1,and the HIF-1α gene knock-out mixed colony cell were selected using puromycin. Subsequently,the expression level of HIF-1α in the HIF-1α gene knock-out mixed colony cell lines was detected by Western blot. Results: Through the sequencing validation,the plasmids targeting HIF-1α gene was successfully constructed. The expression levels of HIF-1αin Hep G2 and SK-Hep-1 transfected with the recombinant vector were significantly reduced. Conclusion: CRISPR/Cas9 plasmid targeting HIF-1α gene has been successfully constructed.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2016年第3期293-297,共5页 Journal of Zhengzhou University(Medical Sciences)
基金 河南省科技厅创新人才基金项目124100510010 郑州大学第一附属医院青年基金项目(2013年)
关键词 HIF-1Α CRISPR/Cas9 肝细胞癌 载体构建 基因敲除 HIF-1α CRISPR/Cas9 hepatocellular carcinoma vector construction gene knock-out
  • 相关文献

参考文献13

  • 1CHEN JG,ZHANG SW. Liver cancer epidemic in China: past, present and future [ J ]. Semin Cancer Biol, 2011,21 (1) :59.
  • 2BRUIX J, SHERMAN M. Management of hepatocellular carcinoma : an update [ J ]. Hepatology ,2011,53 ( 3 ) : 1020.
  • 3RANKIN EB, GIACCIA AJ. The role of hypoxia-inducible factors in tumorigenesis [ J ]. Cell Death Differ, 2008, 15 (4) :678.
  • 4POUYSSIGUR JD, MAZURE NM. Hypoxia signalling in cancer and approaches to enforce turnout regression [ J ]. Nature ,2006,441 (7092) :437.
  • 5ZHONG H, DE MARZO AM, LAUGHNER E, et al. Over- expression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases [ J ]. Cancer Res, 1999,59(22) :5830.
  • 6DAI CX, GAO Q, QIU SJ, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery[ J ]. BMC Cancer,2009,9 ( 1 ) : I.
  • 7SANDER JD,JOUNG JK. CRISPR-Cas systems for editing, regulating and targeting gunomes [ J ]. Nat Bioteehnol, 2014,32(4) :347.
  • 8孙冉冉,陈晓龙,李娟,申申,李晶晶,阚全程,余祖江.靶向PD-L1基因的CRISPR/Cas9基因敲除质粒的构建[J].郑州大学学报(医学版),2016,51(1):22-27. 被引量:2
  • 9WANG GL, SEME/ZA GL. Purification and characteriza- tion of hypoxia-inducible factor I [ J ]. J Biol Chem, 1995, 270 ( 3 ) : 1230.
  • 10SEMENZA GL. Defining the role of hypoxia-inducible fac-tot 1 in cancer biology and therapeutics [ J ]. Oncogene, 2010,29(5) :625.

二级参考文献16

  • 1IWAI Y,ISHIDA M,TANAKA Y,et al. Involvement of PD- L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-LI blockade [ J ]. Proc Natl Acad Sci U S A,2002,99(19):12293.
  • 2DONG H,STROME SE,SALOMAO DR, et al. Tumor-asso- ciated B7-H1 promotes T-cell apoptosis: a potential mech- anism of immune evasion [ J ]. Nat Med,2002,8 ( 8 ) : 793.
  • 3THOMPSON RH, KUNTZ SM,LEIBOVICH BC ,et al. Tumor B7-H1 is associated with poor prognosis in renal cell carci- noma patients with long-term follow-up [ J ]. Cancer Res, 2006,66(7) :3381.
  • 4GAO Q, WANG XY, QIU SJ, et al. Overexpression of PD- L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma [ J ]. Clin Cancer Res,2009,15 ( 3 ) :971.
  • 5OHAEGBULAM KC, ASSAL A, LAZAR-MOLNAR E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway [ J ]. Trends Mol Med,2015,21 (1) :24.
  • 6COX DB, PLATT RJ, ZHANG F. Therapeutic genome edi- ting : prospects and challenges[ J ]. Nat Med,2015,21 (2 : 121.
  • 7CONG L, RAN FA, COX D, et al. Multiplex genome engi- neering using CRISPR/Cas systems[ J]. Science,2013,339 (6121) :819.
  • 8HANAHAN D, WEINBERG RA. Hallmarks of cancer: the next generation [ J ]. Cell, 2011,144 ( 5 ) : 646.
  • 9RIBAS A,TUMEH PC. The future of cancer therapy : selec-ting patients likely to respond to PD1/L1 blockade [ J ]. Clin Cancer Res ,2014,20( 19 ) :4982.
  • 10BARRANGOU R, FREMAUX C, DEVEAU H, et al. CRISPR provides acquired resistance against viruses in prokaryotes [J]. Science,2007,315(5819) :1709.

共引文献1

同被引文献10

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部